Eli Lilly and Company
Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
DitchCarbon Score
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eli Lilly and Company's score of 55 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eli Lilly and Company's reported carbon emissions
Eli Lilly and Company, headquartered in Great Britain, has made significant strides in addressing its carbon emissions and climate commitments. In 2023, the company reported total emissions of approximately 5,184,000 kg CO2e, comprising 182,000,000 kg CO2e from Scope 1, 345,000,000 kg CO2e from Scope 2, and 5,139,500,000 kg CO2e from Scope 3 emissions. This reflects a comprehensive approach to emissions management across all scopes. Eli Lilly has set an ambitious target to achieve carbon neutrality in its operations by 2030, encompassing all scopes of emissions. This commitment underscores the company's dedication to sustainability and aligns with industry standards for climate action. Historically, Eli Lilly's emissions have shown fluctuations, with notable figures from previous years including 710,000,000 kg CO2e in 2020 and 1,000,000 kg CO2e in 2019. The company continues to focus on reducing its carbon footprint through various initiatives aimed at improving operational efficiency and sustainability practices. Overall, Eli Lilly's proactive stance on climate commitments positions it as a leader in the pharmaceutical industry, striving for a sustainable future while addressing the challenges of climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2010 | 2011 | 2012 | 2013 | 2014 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 527,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 14,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
